Pharmacovigilance

Pharmacovigilance encompasses the systematic detection, assessment, understanding, and prevention of adverse drug reactions, serving as the cornerstone of patient safety throughout a therapeutic's lifecycle. This critical discipline extends beyond regulatory compliance, representing a proactive commitment to monitoring medication safety from clinical trials through decades of post-marketing use.

Effective pharmacovigilance programmes aggregate data from spontaneous reporting systems, electronic health records, patient registries, and social media surveillance to identify potential safety signals. When unexpected adverse events emerge, pharmacovigilance teams rapidly investigate causality, implement risk mitigation strategies, and communicate findings to healthcare providers and patients. The biopharmaceutical industry faces evolving challenges with novel modalities including cell therapies, gene therapies, and complex biologics. Regulatory authorities worldwide mandate robust pharmacovigilance systems, with the European Medicines Agency and FDA requiring risk management plans for new molecular entities. Companies invest substantially in pharmacovigilance infrastructure, recognising that comprehensive safety monitoring protects patients while preserving brand reputation. Advanced analytics and artificial intelligence now augment traditional pharmacovigilance approaches, enabling faster signal detection and more nuanced benefit-risk assessments.